Sanguine Corporation Receives Update from PHER-O2 Manufacturer
6:00 AM ET - BusinessWire
Sanguine Corporation (OTC Bulletin Board: SGNC) is pleased to announce that a meeting was held at the office in West Chester, Pennsylvania, with the Company's GMP pharmaceutical manufacturer of PHER-O2 to discuss the product's progress and stage of development. With the recent supply of PHER-O2 to a European medical research group for intravenous development and evaluation, Sanguine management elected to discuss the progress of PHER-O2's master drug file, improved manufacturing and requirements necessary for long term supply of product. The details of the meeting were confidential, however both companies' management were quite pleased with the progress and future of PHER-O2 as a transport medium for transplantable materials.
According to Sanguine's spokesperson, Mr. Frank Marra, "The manufacturer is one of Europe's most respected pharmaceutical groups with medical device expertise in the areas of bedside and ambulatory infusion technology, infusion disposables, enteral application technology, auto-transfusions, blood collection and processing. With the intravenous pre-clinical evaluation progressing well, and with the company's readiness to complete the master drug file necessary for a 510(k) device application, it was important to meet with our product manufacturer to discuss ways to expedite avenues to product sales. We expect PHER-O2 to be an integral part of the Company's future, once the 510(k) approval is complete."
About Sanguine
Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on the development of an oxygen-carrying synthetic substitute for human red blood cells and various other areas requiring oxygen profusion. The company is developing a synthetic red blood cell product, PHER-O2, that consists of perfluoro-decalin molecules, purified water, and a proprietary synthetic - patent pending fluorinated surfactant to hold the emulsion together.
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
For Sanguine Corporation Michael Dancy, 801-746-3570 (Investor Relations) medancy@allwest.net
invest at your own risk, based on your own due diligence, at your own risk tolerance
